In our study, we found that there is a significant benefit between the main target B2M gene and its corresponding receptor gene in the hypopharyngeal carcinoma microenvironment, but this target and the corresponding targeting drugs have not been further studied or applied in head and neck cancer. The gene discussed is B2M; the disease is hypopharyngeal carcinoma.